Inovio treats first patient in immuno-oncology study for advanced bladder cancer
Inovio Pharmaceuticals announced it has dosed its first patient in a Phase 1/2a study designed to evaluate the safety, immunogenicity and clinical efficacy of INO-5401, Inovio’s novel cancer immunotherapy that encodes multiple cancer antigens. August 16, 2018